A message from Bellberry
To our valued Bellberry community:
In line with South Australian 6-day circuit breaker restrictions introduced today, Bellberry has closed our Adelaide office. At this stage, the closure is planned for 19th-24th November and will be reviewed as more information becomes available. We will be working remotely for the time being.
Bellberry HRECs perform an important role: in terms of review of new research, the oversight of ongoing research and the provision of a participant contact pathway. We are committed to ensuring that our work continues in a safe and seamless manner regardless of what happens with COVID this year.
The Bellberry team initially trialled remote working practices in February and moved to fully remote services for the first time in March. Since then, our office occupation rate has flexed up and down according to the COVID environment in South Australia. We see today’s changes as simply the latest stage of this journey.
For our research users who access our services from across the country: it is business as usual for the Bb team (even if our desk locations are not). Our Bb pets are delighted to have us all at home again!
We support our public health colleagues in their work to control this outbreak and thank them for all their efforts.
Kylie Sproston - Chief Executive Officer - Bellberry Ltd
Impact Report 2025
We’re proud to share Bellberry’s 2025 Impact Report - our first report bringing together key insights, data and achievements from the past…
Read More
Bellberry Office Easter Closure 2026
The Bellberry office will be closed for the Easter break on Friday 3 April and Monday 6 April. Reopening at 9am on…
Read More
2026 Podcast Season: More About NAMs
When a potential new medicine is tested on humans for the first time it is a milestone. It is thoroughly tested for…
Read More
Bellberry Newsletter – Summer 2025
Welcome to our newsletter for summer 2025. The Bell contains a roundup of the activities Bellberry has been involved with in the…
Read More
2025-26 Meeting & Submission Dates
Our end of year meeting and submission dates are as follows: The Bellberry office will be closed from COB Wed 24 December…
Read More
Project Officer Vacancy
Project Officer - Adelaide, Full time We're seeking a Project Officer with strong auditing and governance experience to help deliver services that…
Read More
2025/26 Bellberry-Viertel Fellow Announced
Last month at the Australian Academy of Health and Medical Sciences Gala Dinner in Canberra our new Bellberry-Viertel Fellow was announced! Congratulations…
Read More
2025-26 Meeting & Submission Dates
Our end of year meeting and submission dates are as follows: The Bellberry office will be closed from COB Wed 24 December…
Read More
National Statement Updates 2025
The National Statement on Ethical Conduct in Human Research is the principal reference for research involving humans in Australia and is the…
Read More
Operations Update 28
In the September issue of our Operations Update please find articles on: New Bellberry office address New eProtocol registrations contact email Bellberry…
Read More
Bellberry User Satisfaction Survey
As Australia’s largest provider of Human Research Ethics Committee services, Bellberry places great value on understanding the experience our users have of…
Read More
International Research Administrators Day
Today, September 25, we celebrate International Research Administrators Day! This globally recognised day honours the contribution of Research Administrators in supporting and…
Read More
NAMs workshop summary report released
We are pleased to release the summary report from the Bellberry & ASCEPT New Approach Methodologies (NAMs) Introductory Workshop, held in Melbourne,…
Read More
ACTA Trial of the Year Award Winner
On May 20, 2025, the Australian Clinical Trials Alliance (ACTA) hosted its annual Trial of the Year Awards, coinciding with International Clinical…
Read More
Clinical Trial Activity Report (CTAR) 2024
Report highlights international confidence in Australian clinical trials Global investment in Australian clinical trials is strong, with two thirds of Australian clinical…
Read More